LJPC Stock Overview
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
La Jolla Pharmaceutical Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.22 |
| 52 Week High | US$6.24 |
| 52 Week Low | US$3.07 |
| Beta | 2.41 |
| 1 Month Change | 0.49% |
| 3 Month Change | 65.87% |
| 1 Year Change | 59.08% |
| 3 Year Change | -36.92% |
| 5 Year Change | -81.03% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Innoviva to acquire La Jolla Pharma for $149M including debt
Jul 11We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative
Nov 11
Our Take On La Jolla Pharmaceutical Company
Jul 02La Jolla Pharmaceutical EPS misses by $0.14, beats on revenue
May 07La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares
Mar 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Feb 11Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%
Jan 16La Jolla Pharmaceutical rallies on exclusive licensing agreement with PAION
Jan 12Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?
Jan 05Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?
Dec 09La Jolla Pharmaceutical EPS beats by $0.11, beats on revenue
Nov 09Shareholder Returns
| LJPC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | 0.4% | 1.0% |
| 1Y | 59.1% | 0.9% | 21.9% |
Return vs Industry: LJPC exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: LJPC exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| LJPC volatility | |
|---|---|
| LJPC Average Weekly Movement | 23.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LJPC's share price has been volatile over the past 3 months.
Volatility Over Time: LJPC's weekly volatility has increased from 14% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 61 | Larry Edwards | www.lajollapharmaceutical.com |
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States.
La Jolla Pharmaceutical Company Fundamentals Summary
| LJPC fundamental statistics | |
|---|---|
| Market cap | US$155.11m |
| Earnings (TTM) | US$3.97m |
| Revenue (TTM) | US$46.49m |
39.1x
P/E Ratio3.3x
P/S RatioIs LJPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LJPC income statement (TTM) | |
|---|---|
| Revenue | US$46.49m |
| Cost of Revenue | US$8.87m |
| Gross Profit | US$37.62m |
| Other Expenses | US$33.65m |
| Earnings | US$3.97m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 80.92% |
| Net Profit Margin | 8.54% |
| Debt/Equity Ratio | -179.3% |
How did LJPC perform over the long term?
See historical performance and comparison